Article Details
Retrieved on: 2024-06-10 21:06:46
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article discusses GSK's recent FDA approval for the Arexvy respiratory jab to be used in younger patients, highlighting its competitive stance against Pfizer in the vaccine market, which includes COVID-19 vaccines. This development ties in investments and deployment aspects.
Article found on: www.thisismoney.co.uk
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here